Related Experiment Video
Updated: Apr 5, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Glioblastoma Multiforme and Lipid Nanocapsules: A Review
Abstract:
Epidemiological data on central nervous system disorders call for a focus on the major hindrance to brain drug delivery, blood-central nervous system barriers. Otherwise, there is little chance of improving the short-term survival of patients with diseases such as glioblastoma multiforme, which is one of the brain disorders associated with many years of life lost. Targetable nanocarriers for treating malignant gliomas are a unique way to overcome low chemotherapeutic levels at target sites devoid of systemic toxicity. This review describes the currently available targetable nanocarriers, focusing particularly on one of the newest nanocarriers, lipid nanocapsules. All of the strategies that are likely to be exploited by lipid nanocapsules to bypass blood-central nervous system barriers, including the most recent targeting approaches (mesenchymal cells), and novel administration routes (convection enhanced delivery) are discussed, together with their most remarkable achievements in glioma-implanted animal models. Although these systems are promising, much research remains to be done in this field.
Insights
Targetable nanocarriers, like lipid nanocapsules, show promise for overcoming blood-brain barriers to treat brain tumors such as glioblastoma multiforme, improving drug delivery and reducing toxicity.
Area of Science:
- Neuroscience
- Nanotechnology
- Oncology
Background:
- Central nervous system (CNS) disorders, including glioblastoma multiforme, face significant challenges in drug delivery due to the blood-brain barrier (BBB).
- Low chemotherapeutic levels at tumor sites and systemic toxicity limit treatment efficacy for malignant gliomas.
- Effective drug delivery strategies are crucial for improving patient survival rates and quality of life.
Purpose of the Study:
- To review currently available targetable nanocarriers for treating malignant gliomas.
- To focus on lipid nanocapsules as a novel nanocarrier system for brain drug delivery.
- To discuss strategies for bypassing the blood-central nervous system barriers using nanocarriers.
Main Methods:
- Review of existing literature on targetable nanocarriers for brain tumor treatment.
- Focus on lipid nanocapsules and their mechanisms for crossing the blood-central nervous system barriers.
- Discussion of novel targeting approaches, such as mesenchymal cells, and administration routes like convection-enhanced delivery.
Main Results:
- Targetable nanocarriers offer a unique approach to enhance chemotherapeutic levels at glioma sites while minimizing systemic toxicity.
- Lipid nanocapsules demonstrate potential in overcoming blood-central nervous system barriers.
- Recent advancements include utilizing mesenchymal cells for targeting and convection-enhanced delivery for administration.
Conclusions:
- Lipid nanocapsules and other targetable nanocarriers show significant promise for treating malignant gliomas by improving drug delivery across the blood-central nervous system barriers.
- Further research is needed to fully realize the therapeutic potential of these nanocarrier systems in clinical settings.
- Novel administration routes and targeting strategies are key to enhancing the efficacy of nanocarrier-based brain cancer therapies.
